Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in acute coronary syndromes (ACS). However, this therapy encompasses increased bleeding, especially in elderly patients increasingly undergoing percutaneous intervention. Even though most bleeding events might not be fatal (many of them are mostly digestive) they do involve higher hospitalization rate and therefore higher health cost. 

Research on the use of short term DAPT is not new, and outcomes so far have been promising; however, its indication in ACS patients remains unclear. 

The present prespecified analysis of the randomized TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) compares patients with and without prior acute myocardial infarction (AMI), with special attention to evolution with 12 month DAPT vs 3 month DAPT followed by ticagrelor monotherapy + placebo at 12 months. 

6532 patients were randomized: 4595 without prior AMI (70.3%) and 1937 with prior AMI (29,7%).

There were no significant differences between the populations, except for smoking and multivessel disease in patients receiving ticagrelor + aspirin among patients with no prior MI. Among the patients with prior MI there was a higher proportion of insulin dependent diabetes, dyslipidemia, hypertension, multivessel disease, PCI and CABG. 

At one-year followup, global bleeding rate was similar between patients with and without prior AMI (5% vs. 5.5% respectively). However, looking at patients who had received ticagrelor + placebo, the group with prior MI presented less bleeding when compared against patients with no prior MI (3.4% vs. 6.7%; HR: 0.50; 95% CI: 0.33-0.76 and 4.2% vs 7.0%; HR: 0.58; 95% CI:0.45-0.76 respectively). 

Read also: Low Risk Patients: TAVR with Self-Expanding Valves Offers Similar Outcomes to Surgery Based on a Bayesian Analysis?

The presence of death, AMI or stroke was higher in patients with prior AMI (5.7% vs 3.2%; P < 0.001).

There were no differences in cardiac death, non-fatal infarction, non-fatal stroke, BARC bleeding 2.3 or 5, definite or probable thrombosis.

Conclusion

Ticagrelor monotherapy is associated with a significant reduction of bleeding events compared against ticagrelor + aspirin, with no compromise of ischemic prevention among high-risk patients with a history of MI undergoing PCI. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board, SOLACI.org

Original Title: Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. A Prespecified TWILIGHT Substudy.

Reference: Mauro Chiarito, et al. J Am Coll Cardiol Intv 2022;15:282–293.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...